Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efalizumab response classification in moderate to severe plaque psoriasis
2005-000480-25Phase 4Terminated
- Sponsor
- Trondheim Hudlegesenter
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of efalizumab in plaque psoriasis, sponsored by Trondheim Hudlegesenter. Primary endpoints: Psoriasis Area and Severity Index, Psoriasis Disability Index and 1 more. Started Jun 2006; status: terminated.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2005-000480-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000480-25.